Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Prostatic Neoplasms × Etoricoxib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Somatoform Disorders 1 Prostatic Neoplasms 1 Peripheral Nervous System Diseases 1 Breast Neoplasms 1 Breast Neoplasm Female 1

Interventions

Docetaxel 158 Prednisone 130 Leuprolide 95 bicalutamide 86 enzalutamide 84 Radiotherapy 80 Goserelin 80 Abiraterone Acetate 76 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 54 Magnetic Resonance Spectroscopy 46 Zoledronic Acid 44 gallium 68 PSMA-11 36 Flutamide 34 Estramustine 32 abiraterone 30 radium Ra 223 dichloride 29 apalutamide 27 Surveys and Questionnaires 26 Gonadotropin-Releasing Hormone 26 Androgen Antagonists 24 cabazitaxel 23 Radiosurgery 23 Dutasteride 22 sipuleucel-T 21 Prednisolone 21 Triptorelin Pamoate 20 Paclitaxel 20 luprolide acetate gel depot 19 Radiation 19 Exercise 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00427999 2016-11-21

INV342

Novartis

Phase 2 Completed

67 enrolled 6 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡